Table Info

Table 3.

Results of binary logistic regression analysis with high alcohol use index as the dependent variable

Explanatory variables	Wald_df	P value	ORs	95% CI
Male	3.98₁	0.046^*	7.28	1.04–51.12
Lifetime anxiety disorders	5.75₁	0.016^*	6.65	1.91–31.25
Lifetime alcohol dependence	8.30₁	0.009^**	3.91	1.55–9.91
Day per month of MA use	4.73₁	0.030^*	0.95	0.91–0.995

ORs: odds ratio; CI: confidence interval. ^* P < 0.05; ^** P < 0.01

Declarations

Acknowledgments

We thank participants and staff from Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT) for facilitating data collection.

Author contributions

KJ: Methodology, Data curation, Project administration, Writing—original draft. MM: Conceptualization, Formal analysis, Writing—review & editing. NB: Investigation. RK: Methodology, Supervision, Validation, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the Faculty of Medicine, Chulalongkorn University Institutional Review Board (Med Chula IRB), number 155/60 and the Ethical Review Committee for Research in Human Subjects, and the Research Committee, PMNIDAT, and complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

RK was supported for research career by the Centre for Addiction Studies (CADS), Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, and the NIH/NIDA subaward [R01 DA037974], Yale University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Seupsaman B. Substance addiction disorder and alcoholism. In: Tantiphlachiva K, editor. Book of psychiatry, Thailand Psychiatrist Association volume 2. Bangkok: Thammasat university publisher; 1993. pp. 618–51.

Number and percentage of substance abuse treatment services data, divided by fiscal year 2018–2022 [Internet]. Bangkok: Princess Mother National Institute on Drug Abuse Treatment; [cited 2023 May 15]. Available from: http://www.pmnidat.go.th/thai/index.php?option=com_content&task=view&id=3882&Itemid=53

Kittirattanapaiboon P, Tantirangsee N, Chutha W, Tanaree A, Kwansanit P, Assanangkornchai S, et al. Prevalence of mental disorders and mental health problems: Thai national mental health survey 2013. J Ment Health Thai. 2017;25:1–19.

Reungtrakul S. Drugs, silent catastrophe that can be prevented. Bangkok: Ruenkaew printing; 2000.

World report on violence and health [Internet]. Geneva: World Health Organization; [cited 2023 May 15]. Available from: https://apps.who.int/iris/bitstream/handle/10665/67403/a77019.pdf?sequence=1

Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27:253–62. [DOI] [PubMed]

Harwood HJ. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data [Internet]. Bethesda: National Institute on Alcohol Abuse and Alcoholism; [cited 2023 May 20]. Available from: https://pubs.niaaa.nih.gov/publications/economic-2000/alcoholcost.PDF

Pompili M, Serafini G, Innamorati M, Dominici G, Ferracuti S, Kotzalidis GD, et al. Suicidal behavior and alcohol abuse. Int J Environ Res Public Health. 2010;7:1392–431. [DOI] [PubMed] [PMC]

Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al.; ESEMED/MHEDEA Investigators. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. 2007;101:27–34. [DOI] [PubMed]

10.

Christiansen E, Jensen BF. Risk of repetition of suicide attempt, suicide or all deaths after an episode of attempted suicide: a register-based survival analysis. Aust N Z J Psychiatry. 2007;41:257–65. [DOI] [PubMed]

11.

Allgulander C, Allebeck P, Przybeck TR, Rice JP. Risk of suicide by psychiatric diagnosis in Stockholm County. Eur Arch Psychiatry Clin Neurosci. 1992;241:323–6. [DOI] [PubMed]

12.

Möller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl. 2003;108:73–80. [PubMed]

13.

Sareen J, Houlahan T, Cox BJ, Asmundson GJ. Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005;193:450–4. [DOI] [PubMed]

14.

Allebeck P, Allgulander C. Suicide among young men: psychiatric illness, deviant behaviour and substance abuse. Acta Psychiatr Scand. 1990;81:565–70. [DOI] [PubMed]

15.

Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313–21. [DOI] [PubMed]

16.

Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264:2511–8. [PubMed]

17.

Singh VD, Lathrop SL. Youth suicide in New Mexico: a 26-year retrospective review. J Forensic Sci. 2008;53:703–8. [DOI] [PubMed]

18.

Leon AC, Friedman RA, Sweeney JA, Brown RP, Mann JJ. Statistical issues in the identification of risk factors for suicidal behavior: the application of survival analysis. Psychiatry Res. 1990;31:99–108. [DOI]

19.

Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. J Subst Abuse Treat. 2005;29:85–93. [DOI] [PubMed]

20.

Rawson RA, Gonzales RG, Ling W. Methamphetamine abuse and dependence: an update. Dir Psychiatry. 2006;26:221–36.

21.

McKetin R, Mattick RP. Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend. 1998;50:181–4. [DOI] [PubMed]

22.

Kirkpatrick MG, Gunderson EW, Levin FR, Foltin RW, Hart CL. Acute and residual interactive effects of repeated administrations of oral methamphetamine and alcohol in humans. Psychopharmacology (Berl). 2012;219:191–204. [DOI] [PubMed] [PMC]

23.

Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120:135–41. [DOI] [PubMed] [PMC]

24.

Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–14. [DOI] [PubMed]

25.

Jitpong W, Verachai V, Kalayasiri R. Severity of methamphetamine relapses of individuals receiving substance-dependency treatment at Thanyarak Institute. Chula Med J. 2011;55:153–69.

26.

Gossop M, Best D, Marsden J, Strang J. Test-retest reliability of the severity of dependence scale. Addiction. 1997;92:353 [DOI] [PubMed]

27.

Malison RT, Kalayasiri R, Sanichwankul K, Sughondhabirom A, Mutirangura A, Pittman B, et al. Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA). Addict Behav. 2011;36:156–60. [DOI] [PubMed] [PMC]

28.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33. [PubMed]

29.

Kittirattanapaiboon P, Khamwongpin M. The validity of the Mini International Neuropsychiatric Interview (M.I.N.I)-Thai version. J Ment Health Thai. 2005;13:125–35.

30.

Jirakran K, Kalayasiri R. Development of substance outcomes profile to determine consequence of substance use in methamphetamine users. Chula Med Bull. 2019;1:383–91.

31.

Bujarski S, Roche DJ, Lunny K, Moallem NR, Courtney KE, Allen V, et al. The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. Drug Alcohol Depend. 2014;142:127–32. [DOI] [PubMed] [PMC]

32.

Shimosato K. Urinary excretion of p-hydroxylated methamphetamine metabolites in man. II. Effect of alcohol intake on methamphetamine metabolism. Pharmacol Biochem Behav. 1988;29:733–40. [DOI] [PubMed]

33.

Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:105–16. [DOI] [PubMed]

34.

Kalayasiri R, Verachai V, Gelernter J, Mutirangura A, Malison RT. Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort. Addiction. 2014;109:965–76. [DOI] [PubMed] [PMC]

35.

Althobaiti YS, Sari Y. Alcohol interactions with psychostimulants: an overview of animal and human studies. J Addict Res Ther. 2016;7:281. [DOI] [PubMed] [PMC]

36.

Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology. 2014;39:1066–80. [DOI] [PubMed] [PMC]

37.

Doyon WM, Dong Y, Ostroumov A, Thomas AM, Zhang TA, Dani JA. Nicotine decreases ethanol-induced dopamine signaling and increases self-administration via stress hormones. Neuron. 2013;79:530–40. [DOI] [PubMed] [PMC]

38.

Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8:1481–9. Erratum in: Nat Neurosci. 2006;9:979. [DOI] [PubMed]

39.

Cho AK, Melega WP, Kuczenski R, Segal DS. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse. 2001;39:161–6. [DOI] [PubMed]

40.

Schuckit MA. Alcohol, anxiety, and depressive disorders. Alcohol Health Res World. 1996;20:81–5. [PubMed] [PMC]

41.

Brady J. The association between alcohol misuse and suicidal behaviour. Alcohol Alcohol. 2006;41:473–8. [DOI] [PubMed]

42.

Chatterji P, Dave D, Kaestner R, Markowitz S. Alcohol abuse and suicide attempts among youth. Econ Hum Biol. 2004;2:159–80. Erratum in: Econ Hum Biol. 2005;3:164. [DOI] [PubMed]

43.

Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry. 1997;170:205–28. [DOI] [PubMed]

44.

Marshall RA, Smith S, Baumgardner J, Chakrabarti S. Continuous ground-based multiwavelength airglow measurements. J Geophys Res. 2011;116:A11. [DOI]

45.

Kennedy H, Moss G, Birchall C, Moshonas S. Balancing the potential and problems of digital data through action research: methodological reflections. Inf Commun Soc. 2014;18:172–86. [DOI]

46.

Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al.; Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181–90. [DOI] [PubMed]

47.

Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R; Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009;197:225–31. [DOI] [PubMed] [PMC]

48.

Allen KJ, Gabbay FH. The amphetamine response moderates the relationship between negative emotionality and alcohol use. Alcohol Clin Exp Res. 2013;37:348–60. [DOI] [PubMed] [PMC]

49.

Caetano R, Weisner C. The association between DSM-III-R alcohol dependence, psychological distress and drug use. Addiction. 1995;90:351–9. [DOI] [PubMed]

50.

Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender and alcohol consumption: patterns from the multinational GENACIS project. Addiction. 2009;104:1487–500. [DOI] [PubMed] [PMC]

51.

Gonzales R, Ang A, Marinelli-Casey P, Glik DC, Iguchi MY, Rawson RA; Methamphetamine Treatment Project Corporate Authors. Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J Subst Abuse Treat. 2009;37:353–61. [DOI] [PubMed]

52.

Lahmek P, Berlin I, Michel L, Berghout C, Meunier N, Aubin HJ. Determinants of improvement in quality of life of alcohol-dependent patients during an inpatient withdrawal programme. Int J Med Sci. 2009;6:160–7. [DOI] [PubMed] [PMC]

53.

Neale J. Measuring the health of Scottish drug users. Health Soc Care Community. 2004;12:202–11. [DOI] [PubMed]

54.

Chan AM, von Mühlen D, Kritz-Silverstein D, Barrett-Connor E. Regular alcohol consumption is associated with increasing quality of life and mood in older men and women: the Rancho Bernardo study. Maturitas. 2009;62:294–300. [DOI] [PubMed] [PMC]

55.

NIDA research report series: methamphetamine [Internet]. Gaithersburg: National Institute on Drug Abuse; [cited 2023 May 15]. Available from: https://dhs.saccounty.gov/BHS/Documents/SUPT/Methamphetamine/Forum-2018/MA-ADS-2018-Methamphetamine-Forum--NIDA_Methamphetamine_Report.pdf

56.

Vasan S, Olango GJ. Amphetamine toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018. pp. 1–12 [PubMed]

57.

Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V. Methamphetamine: effects on the brain, gut and immune system. Pharmacol Res. 2017;120:60–7. [DOI] [PubMed]

58.

Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24:6028–36. [DOI] [PubMed] [PMC]

59.

Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17:275–97. [DOI] [PubMed]

60.

Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28:1115–26. [DOI] [PubMed] [PMC]